For the first nine months of the year. Geographically, our core Western markets of the Americas and EMEA accounted for 85% of total revenue, with APAC accounting for 15%. So, we saw a very similar trend in Q3. We had recurring revenues of just under 1.1 billion SEK, again representing 72% of total revenue, which was up 39% over 2023. Our gross margins at 63% year to date are robust and ahead of last year. In the quarter, which is traditionally quieter, we did see some transitory changes in product and customer mix. What I would say is do not get too fixated on one particular quarter as our business goes along. Yes, margins in Q3 were a little lighter, but in Q2 they were a little stronger, with an average of 63%. Importantly, we continued to deliver attractive adjusted EBITDA. In fact, in Q3, we delivered an adjusted EBITDA of $124 million, up 6% over Q3 2023. In the first nine months, we've delivered adjusted EBITDA of $380 million, 17% above 2023. In Q3, we delivered adjusted cash flow from operations of $153 million, up 18%, representing 124% of adjusted EBITDA. For the first nine months, we delivered adjusted cash flow from operations of $399 million, up 61%, representing 105% of adjusted EBITDA, demonstrating clearly our ability to successfully convert profits into physical cash. We finished the quarter with gross cash of $370 million and net cash of $120 million for the year. So far, we've funded acquisition earnout payments of approximately $220 million, dividends of $128 million, and investments in intangible and tangible assets of $132 million, totaling approximately $480 million. In total, we've been able to do that because we generate good margins, good profitability, and importantly, we can convert that profit into cash. We continue to invest in our operational facilities to increase manufacturing capacity to enable future attractive growth in the Isle of Man. Additional capacity will come on stream in Q4. In Boston, our new facility has clean rooms so we can more fully exploit the column packing market as well as warehousing for rapid delivery of products to our customers. Additionally, our continued investment in research and development underpins our steady stream of product launches and cements our reputation for thought and innovation leadership in the markets we operate in.
To conclude, we've delivered a very solid Q3 and year-to-date performance, and the business is in good shape as we enter Q4.
Nothing in this Q3 announcement alters our view of the business. The fundamentals are super strong, and Biotage is well placed. We're confident of delivering on our full year '24 targets, and we're now open for questions. Operator. We are now open for questions.